Heart Failure Due To Systemic Left Ventricular Systolic Dysfunction clinical trials

Explore recruiting heart failure due to systemic left ventricular systolic dysfunction clinical trials.

Recruiting heart failure due to systemic left ventricular systolic dysfunction studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Heart Failure Due To Systemic Left Ventricular Systolic Dysfunction trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Single-arm, Open-label Extension of the Vericiguat VALOR Study in Pediatric Participants with Heart Failure due to Systemic Left Ventricular Systolic Dysfunction (VALOR EXT)

Italy, Portugal, Sweden, Denmark, Poland, Belgium +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

(21466) A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to investigate the efficacy, safety, and PK/ PD of finerenone, in addition to standard-of-care, in pediatric patients, 6 months to < 18 years of age, with heart failure (HF) and left ventricular systolic dysfunction (LVSD)

Czechia, Poland, Portugal, Austria, Finland, Greece +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants with Heart Failure due to Systemic Left Ventricular Systolic Dysfunction (VALOR)

Netherlands, Hungary, Portugal, France, Denmark, Spain +8 more

Phase II and Phase III (Integrated) EU CTIS Study details

(21467) A Phase 3, single-arm, open-label extension study to evaluate the safety of finerenone in addition to standard of care, in pediatric heart failure patients, from birth to 18 years of age, with left ventricular systolic dysfunction (LVSD)

Czechia, Germany, Greece, Italy, Finland, Bulgaria +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Heart Failure Due To Systemic Left Ventricular Systolic Dysfunction trials by city

Heart Failure Due To Systemic Left Ventricular Systolic Dysfunction in Toronto Heart Failure Due To Systemic Left Ventricular Systolic Dysfunction in Vancouver Heart Failure Due To Systemic Left Ventricular Systolic Dysfunction in Montreal Heart Failure Due To Systemic Left Ventricular Systolic Dysfunction in Calgary Heart Failure Due To Systemic Left Ventricular Systolic Dysfunction in Edmonton Heart Failure Due To Systemic Left Ventricular Systolic Dysfunction in Ottawa Heart Failure Due To Systemic Left Ventricular Systolic Dysfunction in Winnipeg Heart Failure Due To Systemic Left Ventricular Systolic Dysfunction in Quebec City Heart Failure Due To Systemic Left Ventricular Systolic Dysfunction in Hamilton Heart Failure Due To Systemic Left Ventricular Systolic Dysfunction in Kitchener Heart Failure Due To Systemic Left Ventricular Systolic Dysfunction in London Heart Failure Due To Systemic Left Ventricular Systolic Dysfunction in Halifax Heart Failure Due To Systemic Left Ventricular Systolic Dysfunction in New York Heart Failure Due To Systemic Left Ventricular Systolic Dysfunction in Los Angeles Heart Failure Due To Systemic Left Ventricular Systolic Dysfunction in Chicago Heart Failure Due To Systemic Left Ventricular Systolic Dysfunction in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease